Home » Newsletters » BioWorld

BioWorld

March 2, 1994

View Archived Issues

ALPHA THERAPEUTIC FILES IND

ACTIVIST GROUP PROTESTS MILK LABELING GUIDELINES

ISIS COMPLETES FINAL STAGE OF EQUITY FINANCING

EDITEK SECURES $1M CREDIT LINE

CSI'S CELL TRANSFER AIDS THERAPY ENTERS CLINICALS

APPOINTMENTS AND ADVANCEMENTS

LIDAK TO DEVELOP NEW N-DOCOSANOL INDICATIONS

HEMOSOL ACQUIRES STEM CELL TECHNOLOGY

GENENTECH'S PULMOZYME LAUNCHED IN U.K.

CYTOGEN ENTERS FINANCING AGREEMENT

MAGAININ RAISES $15.3M IN PIPE

NEUROCRINE COMPLETES $30M PRIVATE PLACEMENT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...